RBX1 and cancer: The disruption of this partnership involving the ubiquitination of NFE2L2 through the KEAP1/CUL3/RBX1 complex and its posterior proteasomal degradation, which leads to the constitutive activation of antioxidant response genes is known in several cancer types [54–56].